Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
CLYM is expected to report earnings to rise 17.92% to -15 cents per share on November 18
Q3'25
Est.
$-0.15
Q2'25
Beat
by $0.05
Q1'25
Missed
by $0.16
The last earnings report on August 12 showed earnings per share of -12 cents, beating the estimate of -18 cents. With 803.87K shares outstanding, the current market capitalization sits at 161.28M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CLYM showed earnings on August 12, 2025. You can read more about the earnings report here.